|Seed, 4/2010 |
|Venture Round, 10/2011 |
Axerion Therapeutics, Inc. is a private Connecticut-based biotechnology company focused on developing innovative therapeutics for neurological diseases and injuries with significant unmet medical need, including Alzheimerâ€™s disease and spinal cord injury.
Axerion was established in New Haven to develop and commercialize intellectual property licensed from Dr. Stephen Strittmatterâ€™s laboratory at Yale University. Axerionâ€™s proprietary technology platforms include blockers of ÃŸ-amyloid (AÃŸ) oligomers binding to Prion Proteins (PrP) on the cell surface of neurons as a novel therapeutic target for Alzheimerâ€™s disease and Nogo Receptor decoy protein for recovery of neurological function in spinal cord injury and other neurological diseases.